GlassScriptPhysician profile
Tho Q Nguyen
NPI 1861462020
$15,840.76
in general payments reported to CMS, 2019-2025
47 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,155 · 2020: $2,909 · 2021: $1,852 · 2022: $1,829 · 2023: $2,469 · 2024: $1,903 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,889 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,889.30 |
| Education | $207.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,104.24 | 2019-2025 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $2,561.60 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Abbvie INC. | $1,412.30 | 2019-2025 | |
| Merz North America, INC. | $1,233.86 | 2019-2020 | |
| Genzyme Corporation | $1,217.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $734.64 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $701.30 | 2019-2023 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $568.73 | 2019-2025 | |
| Amgen INC. | $445.51 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $370.83 | 2019-2025 | |
| Dermavant Sciences, INC. | $324.47 | 2023 | Vtama |
| Almirall LLC | $313.17 | 2019-2025 | Seysara, Klisyri |
| Lilly USA, LLC | $250.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $249.43 | 2022-2024 | Sotyktu |
| Incyte Corporation | $225.33 | 2023-2025 | Opzelura |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tho Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.